← Devices & Neurotechnology
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
AP-HP OTOPLAT platinum ototoxicity pharmacogenetics study
Also known as: OTOPLAT, Cancer and deafness associated with platinum derivatives, Platinum ototoxicity pharmacogenetics study
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Diagnostic
Modality
Genetic/Biomarker Study
Stage
Not applicable
Status
Completed
Target Gene
—
Route / Mode
Genetic sequencing
Confidence
88%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
France
Population
pediatric, genetic, cisplatin-ototoxicity
Trial IDs
1
Mechanism
Retrospective case-control genetic study of variants associated with severe platinum-derivative ototoxicity in children with cancer.
Indications
Notes
Registry-verified pharmacogenetics/biomarker study. It is diagnostic/observational genetic research, not gene therapy or a commercial product.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...
IDs: NCT02425397
Key Events
2016-01-05
Clinical Trials (1)
Data Checks
institution-led-studyregistry-only-evidencemerged-generated-intervention-armsgenetic-testing-not-gene-therapydiagnostic-study-not-product
Related Programs
Apple AirPods Pro Hearing Health Features
Company: Apple · Hearing Aid/Software · Marketed
Nuance Audio Hearing Aid Software
Company: EssilorLuxottica · Hearing Aid/Software · Marketed
Cochlear Nucleus Nexa System
Company: Cochlear · Cochlear/Auditory Implant · Marketed
Envoy Medical Acclaim Cochlear Implant
Company: Envoy Medical · Cochlear/Auditory Implant · Phase 2/3
MED-EL SYNCHRONY Cochlear Implant System
Company: MED-EL · Cochlear/Auditory Implant · Marketed
Phonak Audéo Sphere Infinio
Company: Phonak · Hearing Aid/Software · Marketed